Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NMTC NeuroOne Medical Technologies	$0.73 +0.6%	$0.62	$0.40 ▼ $1.39	$36.17M	0.63	185,652 shs	135,275 shs
NURO NeuroMetrix	$4.55 +4.4%	$4.52	$2.66 ▼ $4.73	$9.37M	1.82	16,219 shs	35,522 shs
POCI Precision Optics	$4.57	$4.47	$3.47 ▼ $6.59	$35.03M	0.21	15,594 shs	52,984 shs
PYPD PolyPid	$3.58 -4.3%	$2.99	$2.30 ▼ $4.49	$38.11M	1.25	130,392 shs	109,658 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NMTC NeuroOne Medical Technologies	+0.55%	+6.17%	+19.38%	-15.12%	+8.13%
NURO NeuroMetrix	0.00%	0.00%	0.00%	+2.71%	+22.97%
POCI Precision Optics	0.00%	0.00%	-1.93%	+10.65%	-19.12%
PYPD PolyPid	-4.28%	+8.16%	+40.39%	+30.66%	-12.22%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
NMTC NeuroOne Medical Technologies	2.4324 of 5 stars	3.5	3.0	0.0	0.0	2.6	1.7	0.0
NURO NeuroMetrix	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
POCI Precision Optics	0.1101 of 5 stars	0.0	3.0	0.0	0.0	0.0	0.8	0.0
PYPD PolyPid	3.2059 of 5 stars	3.6	5.0	0.0	0.0	3.1	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NMTC NeuroOne Medical Technologies	3.00	Buy	$1.45	98.63% Upside
NURO NeuroMetrix	0.00	N/A	N/A	N/A
POCI Precision Optics	0.00	N/A	N/A	N/A
PYPD PolyPid	3.17	Buy	$11.80	229.61% Upside

Current Analyst Ratings Breakdown

Latest NURO, PYPD, POCI, and NMTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	PYPD PolyPid	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$12.00 ➝ $9.00
6/17/2025	PYPD PolyPid	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$16.00 ➝ $14.00
6/9/2025	PYPD PolyPid	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $13.00
6/5/2025	PYPD PolyPid	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00
6/2/2025	PYPD PolyPid	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$11.00
5/5/2025	NMTC NeuroOne Medical Technologies	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$1.45
4/14/2025	PYPD PolyPid	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NMTC NeuroOne Medical Technologies	$3.45M	10.54	N/A	N/A	$0.03 per share	24.33
NURO NeuroMetrix	$3.03M	3.09	N/A	N/A	$13.18 per share	0.35
POCI Precision Optics	$19.10M	1.84	N/A	N/A	$1.66 per share	2.75
PYPD PolyPid	N/A	N/A	N/A	N/A	$0.75 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NMTC NeuroOne Medical Technologies	-$12.32M	-$0.22	N/A	∞	N/A	-75.41%	-334.64%	-124.42%	8/13/2025 (Estimated)
NURO NeuroMetrix	-$6.53M	-$4.59	N/A	∞	N/A	-203.71%	-42.56%	-39.26%	8/4/2025 (Estimated)
POCI Precision Optics	-$2.95M	-$0.89	N/A	∞	N/A	-32.84%	-54.03%	-32.48%	N/A
PYPD PolyPid	-$29.02M	-$4.30	N/A	∞	N/A	N/A	-1,069.37%	-151.85%	8/13/2025 (Estimated)

Latest NURO, PYPD, POCI, and NMTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q3 2025	POCI Precision Optics	N/A	-$0.30	N/A	-$0.30	N/A	$4.19 million
5/14/2025	Q1 2025	PYPD PolyPid	-$0.80	-$0.70	+$0.10	-$0.70	N/A	N/A
5/13/2025	Q2 2025	NMTC NeuroOne Medical Technologies	-$0.09	-$0.07	+$0.02	-$0.07	$1.27 billion	$1.39 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
NMTC NeuroOne Medical Technologies	N/A	N/A	N/A	N/A	N/A
NURO NeuroMetrix	N/A	N/A	N/A	N/A	N/A
POCI Precision Optics	N/A	N/A	N/A	N/A	N/A
PYPD PolyPid	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NMTC NeuroOne Medical Technologies	N/A	2.13	1.09
NURO NeuroMetrix	N/A	13.88	12.70
POCI Precision Optics	0.11	1.99	1.26
PYPD PolyPid	4.43	0.71	0.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NMTC NeuroOne Medical Technologies	16.07%
NURO NeuroMetrix	19.40%
POCI Precision Optics	13.71%
PYPD PolyPid	26.47%

Insider Ownership

Company	Insider Ownership
NMTC NeuroOne Medical Technologies	8.90%
NURO NeuroMetrix	7.30%
POCI Precision Optics	12.99%
PYPD PolyPid	24.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NMTC NeuroOne Medical Technologies	20	49.82 million	45.38 million	Optionable
NURO NeuroMetrix	20	2.06 million	1.90 million	Not Optionable
POCI Precision Optics	80	7.67 million	6.67 million	Not Optionable
PYPD PolyPid	80	10.19 million	7.67 million	No Data

NURO, PYPD, POCI, and NMTC Headlines

Recent News About These Companies

PolyPid Ltd. (PYPD) Latest Stock News & Headlines - Yahoo Finance

June 26 at 8:41 PM | finance.yahoo.com

Brokerages Set PolyPid Ltd. (NASDAQ:PYPD) PT at $11.25

June 20, 2025 | americanbankingnews.com

PolyPid (NASDAQ:PYPD) Price Target Lowered to $9.00 at Roth Capital

June 19, 2025 | americanbankingnews.com

PolyPid Secures $26.7 Million in Additional Funding to Extend Runway Ahead of D-PLEX₁₀₀ FDA Approval

June 18, 2025 | nasdaq.com

PolyPid (NASDAQ:PYPD) Price Target Cut to $14.00 by Analysts at JMP Securities

June 18, 2025 | americanbankingnews.com

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

June 16, 2025 | globenewswire.com

PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

June 11, 2025 | globenewswire.com

PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

June 11, 2025 | globenewswire.com

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met ...

June 11, 2025 | seekingalpha.com

Craig-Hallum Reaffirms Their Buy Rating on PolyPid (PYPD)

June 11, 2025 | theglobeandmail.com

PolyPid reports positive phase 3 surgical infection drug trial

June 11, 2025 | en.globes.co.ilE

Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial

June 11, 2025 | finance.yahoo.com

PolyPid price target raised to $13 from $11 at H.C. Wainwright

June 11, 2025 | msn.com

PolyPid shares surge on successful D-PLEX100 trial results

June 9, 2025 | in.investing.com

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript

June 9, 2025 | globenewswire.com

PolyPid’s D-PLEX100 Achieves Positive Phase 3 Results in SHIELD II Trial

June 9, 2025 | tipranks.com

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

June 9, 2025 | globenewswire.com

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

June 8, 2025 | finance.yahoo.com

PolyPid Ltd. to Host Conference Call on June 9 to Report Topline Data from SHIELD II Phase 3 Trial for D-PLEX100

June 6, 2025 | quiverquant.comQ

PolyPid to Host Conference Call and Webcast to Discuss D-PLEXâ‚â‚€â‚€ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

June 6, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NURO, PYPD, POCI, and NMTC Company Descriptions

NeuroOne Medical Technologies NASDAQ:NMTC

$0.73 +0.00 (+0.55%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$0.71 -0.02 (-2.33%)

As of 06/26/2025 07:17 PM Eastern

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.

NeuroMetrix NASDAQ:NURO

$4.55 +0.19 (+4.36%)

Closing price 05/1/2025

Extended Trading

$4.55 0.00 (0.00%)

As of 05/1/2025 07:55 PM Eastern

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

Precision Optics NASDAQ:POCI

$4.57 0.00 (0.00%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$4.58 +0.01 (+0.33%)

As of 06/26/2025 04:04 PM Eastern

Precision Optics Corporation, Inc. designs, develops, manufactures, and sells specialized optical and illumination systems and related components primarily in the United States and the European Economic Area. It offers medical instrumentation products, including endoscopes and endocouplers, as well as other custom imaging and illumination products, such as Microprecision lenses and micro medical cameras, and 3D endoscopes for use in minimally invasive surgical procedures by hospitals and physicians. The company also provides components and assemblies for industrial and military use. It markets its products to medical device companies. The company was incorporated in 1982 and is based in Gardner, Massachusetts.

PolyPid NASDAQ:PYPD

$3.58 -0.16 (-4.28%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$3.62 +0.04 (+1.12%)

As of 05:05 AM Eastern

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time